Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
IgA nephropathy (IgAN) is the most common primary glomerulonephritis in adults. Its pathogenesis involves immune complexes with aberrantly glycosylated IgA1, which drive complement activation; both alternative and lectin complement pathways contribute to disease progression, and terminal complement complex (C5b-9) deposition correlates with adverse renal outcomes. Eculizumab, a monoclonal antibody against complement component C5, inhibits C5 cleavage and C5b-9 formation to reduce complement-mediated glomerular injury, but clinical evidence for its use in IgAN remains limited.
We conducted a single-center retrospective analysis of 8 biopsy-proven IgAN patients (March 2024–September 2025) with inadequate response to conventional therapy or contraindications to corticosteroids. Eculizumab was dosed 900 mg weekly for 4 weeks, then 1,200 mg every 2 weeks as indicated. Background therapies were initiated and maintained for ≥4 weeks before eculizumab. Serum creatinine (Scr), estimated glomerular filtration rate (eGFR), and 24-hour proteinuria were assessed at baseline and weeks 2, 4, 8, and 12. Adverse events (AEs) were recorded.
All patients had mesangial C3 deposition on immunofluorescence; most had Oxford C1–C2 crescents. At baseline, medians (IQR) were: Scr 225.45 (167.70–582.32) μmol/L; eGFR 23.55 (10.79–46.25) mL/min/1.73 m²; and proteinuria 10.53 (5.78–13.03) g/24 h; one patient was receiving hemodialysis. By Week 4, median Scr decreased to 187.13 μmol/L (−18.2%), eGFR increased to 27.91 mL/min/1.73 m² (+27.9%), and proteinuria fell to 4.59 g/24 h (−57.0%); four patients achieved ≥50% reduction in proteinuria. Two patients had follow-up to week 12 with sustained improvement. The dialysis patient remained dialysis-dependent but had increased urine output. AEs were mild (nasopharyngitis, headache) and resolved with symptomatic management; no severe AEs occurred.
In this small, real-world series, C5 inhibition with eculizumab was associated with early improvements in kidney function and proteinuria and was well tolerated. Larger, controlled studies with longer follow-up are warranted to confirm efficacy and safety in IgAN.
